company background image
GHRS

GH ResearchNasdaqGM:GHRS Stock Report

Market Cap

US$1.0b

7D

-13.2%

1Y

n/a

Updated

04 Dec, 2021

Data

Company Financials +
GHRS fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

GHRS Stock Overview

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders.

Price History & Performance

Summary of all time highs, changes and price drops for GH Research
Historical stock prices
Current Share PriceUS$19.26
52 Week HighUS$30.43
52 Week LowUS$12.38
Beta0
1 Month Change-21.61%
3 Month Change-12.49%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO0.052%

Recent News & Updates

Sep 30
GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans

GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Aug 15

GH Research: A Recent IPO Stock That Could Possibly Be A Trailblazer In A Hot Industry

The WHO predicts that depression will be the biggest problem in the world during the next decade and beyond. GH Research had a rather successful IPO on the 24th of June. Investing in biotech may be the way to go for investors looking for large gains over the long term.

Shareholder Returns

GHRSUS PharmaceuticalsUS Market
7D-13.2%-2.3%-2.7%
1Yn/a11.6%16.6%

Return vs Industry: Insufficient data to determine how GHRS performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how GHRS performed against the US Market.

Price Volatility

Is GHRS's price volatile compared to industry and market?
GHRS volatility
GHRS Average Weekly Movement15.5%
Pharmaceuticals Industry Average Movement9.4%
Market Average Movement6.1%
10% most volatile stocks in US Market14.8%
10% least volatile stocks in US Market2.4%

Stable Share Price: GHRS is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: Insufficient data to determine GHRS's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
20188Theis Terweyhttps://www.ghres.com

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that is being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD.

GH Research Fundamentals Summary

How do GH Research's earnings and revenue compare to its market cap?
GHRS fundamental statistics
Market CapUS$1.00b
Earnings (TTM)-US$3.66m
Revenue (TTM)n/a

0.0x

P/S Ratio

-273.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GHRS income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
ExpensesUS$3.66m
Earnings-US$3.66m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.07
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did GHRS perform over the long term?

See historical performance and comparison

Valuation

Is GH Research undervalued compared to its fair value and its price relative to the market?

3.48x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate GHRS's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate GHRS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: GHRS is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: GHRS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GHRS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: GHRS is overvalued based on its PB Ratio (3.5x) compared to the US Pharmaceuticals industry average (2.6x).


Future Growth

How is GH Research forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

-44.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GHRS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GHRS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GHRS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: GHRS is forecast to have no revenue next year.

High Growth Revenue: GHRS is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: GHRS is forecast to be unprofitable in 3 years.


Past Performance

How has GH Research performed over the past 5 years?

-869.2%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: GHRS is currently unprofitable.

Growing Profit Margin: GHRS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Unable to establish if GHRS's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare GHRS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GHRS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).


Return on Equity

High ROE: GHRS has a negative Return on Equity (-1.27%), as it is currently unprofitable.


Financial Health

How is GH Research's financial position?


Financial Position Analysis

Short Term Liabilities: GHRS's short term assets ($292.8M) exceed its short term liabilities ($4.6M).

Long Term Liabilities: GHRS has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: GHRS is debt free.

Reducing Debt: GHRS has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GHRS has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: GHRS has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 100.6% each year


Dividend

What is GH Research current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate GHRS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GHRS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GHRS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GHRS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GHRS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.9yrs

Average management tenure


CEO

Theis Terwey (45 yo)

0.58

Tenure

Mr. Theis Terwey, MD, PD, Dr. Med, is Chief Executive Officer at GH Research PLC since May 2021. He co-founded GH Research PLC in 2018 and was its Director from 2018 to 2020. Mr. Terwey also serves as a Se...


Leadership Team

Experienced Management: GHRS's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.


Board Members

Experienced Board: GHRS's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: GHRS only recently listed within the past 12 months.


Top Shareholders

Company Information

GH Research PLC's employee growth, exchange listings and data sources


Key Information

  • Name: GH Research PLC
  • Ticker: GHRS
  • Exchange: NasdaqGM
  • Founded: 2018
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.002b
  • Shares outstanding: 52.02m
  • Website: https://www.ghres.com

Number of Employees


Location

  • GH Research PLC
  • 28 Baggot Street Lower
  • Dublin 2
  • Dublin
  • Co. Dublin
  • D02 NX43
  • Ireland

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/04 00:20
End of Day Share Price2021/12/03 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.